Sign in Subscribe
Genetic research

Novel Gene Therapy Shows Promise in Treating Heart Failure

Strategic Insights

— 1 min read

New research published in the Biochemical and Biophysical Research Communications journal has demonstrated the effectiveness of a novel gene therapy in treating heart failure. The study, conducted by a team of researchers from the Veterans Affairs Medical Center in New York, successfully restored ejection fraction (EF) in mice with heart failure using a Cav1.3-C-terminus gene therapy. This breakthrough could potentially lead to new treatments for heart failure, which affects approximately 6.7 million Americans.

Key Takeaways:

  • The Cav1.3-C-terminus gene therapy increased L-type calcium current in mice with heart failure, leading to a normalization of left ventricular EF.
  • Treatment with the gene therapy resulted in resistance to inducible arrhythmias in mice with heart failure.
  • The Cav1.3-C-terminus gene therapy upregulated the expression of Cav1.3, leading to an optimal increase in L-type calcium current.
  • The study demonstrated that the gene therapy was effective in mice with heart failure caused by ischemia-induced murine heart failure.
  • The researchers concluded that the AAV9-Cav1.3-C-terminus may be a novel therapeutic approach to improve cardiac function in heart failure patients.
  • The study highlights the potential of gene therapy in treating heart failure, a condition that affects millions of people worldwide.

Statistics:

  • Approximately 6.7 million Americans are affected by heart failure.
  • 15 days post-ligation of the left-anterior-descending coronary artery (LAD), WT-HF mice displayed fibrosis, impaired wall motion, and decreased left ventricular EF and fractional shortening.
  • At day 30 post-AAV9-Cav1.3-C-terminus-treatment, WT-HF mice showed a significant increase in L-type calcium current (114.2 ± 23.8 pA/pF vs 44.6 ± 10.2 pA/pF in the vehicle-treated group).
  • CACN1D, encoding Cav1.3, was upregulated 1.9-Log2-fold in the AAV9-Cav1.3-C-terminus-treated group vs. vehicle.

Sources:

  • Biochemical and Biophysical Research Communications (2025;779:152455)
  • Veterans Affairs Medical Center, New York, NY, United States
  • Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA (Elsevier - www.elsevier.com; Biochemical and Biophysical Research Communications - www.journals.elsevier.com/biochemical-and-biophysical-research-communications/)
  • NewsRx LLC, Cardiovascular Week (September 22, 2025; p 171)

Read more